Compendia seeks opportunities with selected partners that provide high value to our customers by adding appropriate analysis, content, and services. As our collection of high-throughput data expands the value of integrating third party applications and content becomes apparent. Our focus in developing these partnerships is based on the needs of our customers and leading bioinformatics initiatives. With this in mind Compendia identifies a limited number of partnerships that provide immediate value to our customers.

To learn more about partnering with Compendia, pleasecontact us.

Ingenuity Systems
Ingenuity Systems enable researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies.

Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan.

Integration of Oncomine with Ingenuity Pathways Analysis
A key strength of the Oncomine system is the ease and speed at which abstract relationships between disparate concepts such as drug treatments and patient response can be identified. The scale, diversity, and independent nature of the data in the Oncomine system reinforces confidence in results. When coupled with the Ingenuity Pathways Analysis, researchers are enabled with powerful tools to develop and test hypotheses, and then explore the causal basis for disease and clinical outcome at the systems level.

Customers can navigate the large collection of public cancer profiling data (and internal data for Oncomine Enterprise edition customers) in Oncomine Professional and make comparisons, identify significant relationships, resulting gene lists. Analysis continues directly in Ingenuity Pathways Analysis with a subset of genes identified from a particular study and analysis in Oncomine. This capability enables valuable insights to be gained on how dysregulated genes interact in disease and potential targets for drugs. It also provides a large collection of gene expression studies that function as a virtual laboratory for further refinement in Ingenuity Pathways Analysis.

This integration is currently available to all valid commercial Oncomine subscribers.